Biomerica offers new coeliac disease test:
This article was originally published in Clinica
Biomerica's diagnostics division is adding GliaQuant IgG to monitor gliadin, a protein that causes coeliac disease. Coeliac disease is an inherited autoimmune response of the gastrointestinal tract to traces of gliadin in the gluten of wheat, barley, rye and oats. The disease could affect as many as one in 250 Americans, although fewer than one in 4,700 of the US population has been diagnosed. The product joins a rapidly increasing range of gastrointestinal diagnostic products, including H Pylori and a food allergens kit. The Newport Beach, California-based company says that it will introduce one more digestive disease product in the next few months. The GliaQuant test is available outside the US.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.